Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
WESTLAKE VILLAGE, Calif., Sept. 01, 2017 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for patients with diseases such as diabetes, announced today that it will present at upcoming conferences.
- Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 9:35 am (ET) at the Lotte New York Palace in New York
- Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 9:10 am (ET) at the InterContinental New York Barclay Hotel in New York
Presenting from the Company will be its Chief Executive Officer, Michael Castagna.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP Investor Relations 818-661-5055 [email protected]
